Medication info
Istarplus Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Istarplus Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Intrabiopharma Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500350 · Approved 2025.02.17

Summary

Main use
Treatment of hypertension and dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or telmisartan 40mg. - 80/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or this medicine 40/5mg. - 40/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg. - 80/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg or this medicine 40/10mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. However, treatment should be initiated at a lower dose in patients with severe renal impairment, and the dose should be increased gradually. Regular monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a lower dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Ethnicity: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of rosuvastatin 40mg is contraindicated in some of these patients.

Ingredients

Manufacturer
Intrabiopharma Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used in patients taking the combination of telmisartan and amlodipine who do not have adequate blood pressure control and must also take rosuvastatin. The telmisartan and amlodipine combination helps effectively control blood pressure and is suitable for the treatment of essential hypertension. Rosuvastatin is used as an adjunctive treatment for patients with hypercholesterolemia and mixed dyslipidemia who are not controlled by diet alone. It is also utilized as an adjunctive treatment for patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. This medication is used to lower total cholesterol and LDL cholesterol levels, delay the progression of atherosclerosis, and reduce the risk of cardiovascular diseases, stroke, myocardial infarction, and vascular revascularization procedures. Therefore, it is effective in improving both blood pressure and lipid management.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single-ingredient product may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or telmisartan 40mg. - 80/5mg: For patients whose blood pressure is not adequately controlled with amlodipine 5mg or this medicine 40/5mg. - 40/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg. - 80/10mg: For patients whose blood pressure is not adequately controlled with amlodipine 10mg or this medicine 40/10mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. However, treatment should be initiated at a lower dose in patients with severe renal impairment, and the dose should be increased gradually. Regular monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a lower dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Ethnicity: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of rosuvastatin 40mg is contraindicated in some of these patients.

Precautions

This medication may cause severe harm to the fetus during pregnancy, thus treatment should be stopped immediately upon confirmation of pregnancy. Patients with allergies to this medication's components or certain diseases should not take it. For example, patients with hereditary angioedema or severe liver or kidney impairment are prohibited from taking it. Elderly patients, individuals with compromised liver function, or patients with very low blood pressure should use this medication cautiously, and dosage adjustments may be necessary. If symptoms such as muscle pain or weakness occur during treatment, consult a doctor immediately and regular checks for muscle-related complications should be conducted. If there is liver function abnormality or increased liver enzyme levels, discontinuation of this medication should be considered, and regular liver function tests are recommended. This medication may interact with other drugs, so inform healthcare providers about any other medications being taken. Be cautious of dizziness or drowsiness when driving or operating machinery. Women who may become pregnant should use appropriate contraception, and breastfeeding women should avoid this medication or stop breastfeeding. Safety and effectiveness have not been sufficiently established for pediatric patients or adolescents under 18 years old, thus use is not recommended. In cases of overdose, symptoms such as hypotension, dizziness, and heart issues can occur; immediate emergency treatment is necessary, and appropriate measures should be taken as directed by a physician. This medication should be kept out of the reach of children, and transferring it to another container should be avoided.

Side effects

Viral upper respiratory tract inflammation, respiratory distress, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, infection, fungal infection, abscess, otitis media, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, dizziness, sensory disturbance, involuntary muscle contraction, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disease, gout, hypercholesterolemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, neurosensitivity, angioedema, vasculitis, thrombocytopenia, thrombocytopenia, angioedema, polymorphic erythema, pruritus, rash, erythematous rash, papulovesicular rash, visual disturbances, conjunctivitis, diplopia, ocular pain, tinnitus, ear pain, frequent urination, urinary disorders, nocturia, dry mouth, increased perspiration, hyperglycemia, thirst, leukopenia, edema, headache, dizziness, low back pain, sinusitis, diarrhea, pharyngitis, autonomic nervous system disorders, erectile dysfunction, fever, leg pain, lethargy, fatigue, weakness, facial edema, lower limb edema, thrombocytopenia, increased uric acid, abnormal liver function, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, muscle cramps, myalgia, myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hematuria, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, memory loss, peripheral neuropathy, cough, interstitial lung disease, sexual dysfunction, gynecomastia, depression, sleep disorders, insomnia, nightmares, confusion, exfoliative dermatitis, photosensitivity reaction, toxic epidermal necrolysis, heart failure, irregular pulse, extrasystole, skin depigmentation, skin dryness, hair loss, dermatitis, muscle weakness, single contraction, coordination dysfunction, excessive muscle tension, moist and cold skin, apathy, anxiety, memory loss, gastritis, increased appetite, loose stools, rhinitis, urinary disorders, polyuria, abnormal olfaction, taste disturbance, abnormal eye movement control, dry eyes, angioedema, vasculitis, orthostatic hypotension, dizziness, palpitations, orthostatic hypotension, position-induced dizziness, skeletal pain, osteoporosis, dysuria, rhinitis, oropharyngeal discomfort, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, sensory loss, movement disorders, atherosclerosis, frequency of urination, tinnitus, hearing loss, bad breath

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that protects it from light, as it is sensitive to light. Additionally, to maintain the effectiveness of the medication, it is important to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.